When the leading creatine researchers in the world sit on one stage and take unfiltered questions, you learn what the science actually says, not what the marketing says. That is exactly what happened at a panel session of the Creatine Conference 2022, where Dr. Richard Kreider moderated a discussion featuring Dr. Abbie Smith-Ryan, Dr. Kylie Harmon, Dr. Darren Candow, Dr. Eric Rawson, and Dr. Bruno Gualano, several of the most published scientists in the field.
The conference itself covered enormous ground. Sessions examined creatine for musculoskeletal disease, for women across the menstrual cycle, pregnancy, and the postpartum period, for conditions of aging such as sarcopenia, dynapenia, and osteopenia, and for cognitive health in situations like mild traumatic brain injury, Alzheimer’s disease, and depression. Later sessions explored creatine in immune function, cancer biology, heart and vascular health, and inflammatory bowel disease. The panel we are drawing from distilled much of that into direct answers on the brain, women’s dosing, rehabilitation, muscle differences, blood sugar, and caffeine.
This article organizes what the panelists said, checks their key claims against published, peer reviewed research, and tells you plainly where the evidence is strong, where it is promising, and where it is still early. That last part matters. Creatine has one of the deepest evidence bases of any supplement for muscle and performance, but its newest frontier, the brain, is a different story, and the researchers themselves were refreshingly honest about that.
Creatine and the Brain
Creatine’s job in the body is energy logistics. Cells store it as phosphocreatine, a rapid reserve that regenerates ATP, the molecule that powers nearly everything a cell does. Muscle uses this system during hard efforts. The brain, which consumes an outsized share of the body’s energy, uses it constantly.
Here is the problem the panel kept returning to: getting extra creatine into the brain is much harder than getting it into muscle. Rawson, who has helped lead much of the research on creatine and cognition, put it in stark terms. Skeletal muscle seems built to absorb creatine from the bloodstream, while the brain seems built to resist it. The brain sits behind the blood brain barrier, its creatine transporters are limiting, and it synthesizes a meaningful share of its own creatine internally. Rawson warned that researchers who study the brain as if it behaves like muscle tissue will be led astray.
The published literature backs him up. A 2021 review in Nutrients by Roschel, Gualano, Ostojic, and Rawson concluded that supplementation raises brain creatine far less reliably than muscle creatine, and that higher doses or longer durations than the standard muscle protocols may be required to move brain levels at all. That is a crucial caveat for anyone reading enthusiastic headlines about creatine and cognition.
So does raising brain creatine actually do anything? The evidence is real but modest. A systematic review of randomized trials by Avgerinos and colleagues in 2018 found that creatine may improve short term memory and measures of intelligence and reasoning in healthy people, while effects on other cognitive domains were inconclusive. A pooled analysis by Prokopidis and colleagues in 2023 found memory improvements with supplementation, with the clearest effects in older adults. Reviews also point to potential benefits in stressed states such as sleep deprivation, when the brain’s energy demands spike. None of this makes creatine a cognitive miracle. It makes it a plausible, cheap, and safe support for brain energy metabolism whose effects in healthy people appear small and situation dependent.
The panel also discussed a more experimental route into the brain: guanidinoacetic acid, usually shortened to GAA. GAA is the natural precursor the body converts into creatine, and Candow highlighted work by Dr. Sergej Ostojic showing that around 3 grams of GAA per day can raise brain creatine content, apparently more effectively than creatine monohydrate itself. Intriguingly, GAA seems to favor the brain over muscle, almost the mirror image of creatine’s usual pattern. The study he referenced, a superiority pilot trial published by Ostojic and colleagues in 2016, found that 3 grams of GAA daily for four weeks outperformed the same dose of creatine for increasing brain creatine in healthy men.
Before anyone rushes to buy GAA, the honest caveats: the trial was tiny, the research base is thin, and GAA supplementation can raise homocysteine, an amino acid linked at elevated levels to cardiovascular concerns, because converting GAA to creatine consumes methyl groups. The panelists treated GAA as exactly what it is, a fascinating research lead in the effort to raise brain creatine, with dose response studies still to be done. Rawson agreed that compounds which bypass the transporter bottleneck are promising for brain health, and that there is an enormous amount of work left in this area. For now, creatine monohydrate remains the only option with a meaningful evidence base behind it.
The Case for Concussion Protection
The most compelling stretch of the panel came when Kreider posed a pointed question. Given creatine monohydrate’s known safety profile, its low cost, its effects on recovery and rehabilitation, and animal data suggesting it may reduce the damage from brain injury and ischemia, are we at the point where it is simply prudent to recommend about 3 grams per day to people at risk?
Rawson answered first, and clearly: yes, for individuals at high risk of mild traumatic brain injury. His reasoning was practical rather than promotional. Creatine is inexpensive, widely available, and carries an excellent safety record along with well established muscular benefits, so an athlete in a collision sport, a soldier, or someone in a hazardous occupation loses nothing by taking it. He added that mild traumatic brain injury depletes brain creatine, which gives the recommendation a mechanistic logic: enter the injury with fuller reserves.
Rawson framed this as part of a larger shift in nutrition science. For a century, the field focused on eradicating deficiency diseases. Now it is increasingly asking how much of certain nutrients, even nonessential ones, promotes optimal health. A small daily dose of creatine, he argued, fits that model for older adults, for people at risk of brain injury, and for several other populations. He also shared that sports dietitians working with American collision sports have told him they are ready to act on this, giving creatine prophylactically to players with concussion histories for brain health reasons, on top of the performance rationale.
Kreider agreed and pointed to the 2017 position stand of the International Society of Sports Nutrition, which he led. That document concluded that creatine monohydrate is one of the most effective ergogenic supplements available and that doses up to 30 grams per day for as long as five years have proven safe and well tolerated in healthy people. Weighing that safety record against the potential benefits, Kreider went so far as to argue that keeping creatine away from athletes who stand to benefit comes close to professional negligence. He also cited data comparing athletes who use creatine with those who do not, saying users get injured less and return to play faster, and noted that starting creatine before an injury makes far more sense than starting after one, since the brain takes so long to load.
Some of that is verifiable, some is interpretation. The injury data Kreider referenced traces largely to work by Mike Greenwood and colleagues, who tracked collegiate football players across a season and found that creatine users experienced less cramping, less muscle tightness, fewer muscle strains, and fewer total injuries than nonusers. That study is real and published, but it was observational: players chose for themselves whether to take creatine, which leaves room for other differences between the groups. The faster return to play claim is Kreider’s reading of the broader data rather than a single definitive trial.
What about humans with actual brain injuries? The most direct evidence comes from a Greek research group led by Sakellaris, who gave children and adolescents with severe traumatic brain injury creatine at 0.4 grams per kilogram of body weight daily for six months. The treated group showed better recovery across several measures, including shorter intensive care stays, and a later report from the same program found less headache, dizziness, and fatigue in the months after injury. These results are genuinely encouraging, but they came from small, open label pilot trials in children, and they addressed treatment after injury, not prevention. No randomized trial in humans has yet tested whether taking creatine beforehand protects against concussion or reduces its severity. The panelists know this, which is why the conversation turned to what such a trial would take.
The Missing Concussion Trials
Gualano, whose group in Brazil leads clinical creatine research, raised the uncomfortable methodological question. If the rationale is so strong, why has nobody run a longitudinal randomized controlled trial? His answer was built into the question: concussions are hard to anticipate, so you would need to supplement an enormous number of athletes just to accumulate enough injury events to compare groups. The field’s most important study is also one of its most expensive.
Then Candow made news. A Canadian group, he revealed, was preparing an application that fall to CIHR, Canada’s counterpart to the NIH, for exactly this trial. The plan: randomize roughly 300 university athletes to creatine or placebo before any concussion occurs, taking advantage of a concussion prevalence he put at around 15 percent per year in Canadian university sport, then track recovery with tools including transcranial magnetic stimulation. Dr. Philip Chilibeck would lead the multisite effort, with Dr. Scott Forbes among the investigators. The design would answer two questions at once: whether creatine improves aspects of brain health in the uninjured, and whether it speeds recovery in those who do suffer trauma. Candow noted the implications reach well beyond varsity sport, to children, car accidents, boxing, and mixed martial arts. As of this writing, we could not find published results from this trial, so treat it as a study to watch rather than evidence in hand.
Kreider described a complementary American approach. Universities are increasingly installing MRI and magnetic resonance spectroscopy systems near their athletic facilities, and he gave the University of Nebraska as an example where every incoming athlete is scanned, creating a baseline against which injuries can be quantified. Linking such campuses into a research network could let scientists compare creatine users and nonusers before and after injury at scale. The catch, again, is numbers: by his estimate only about 5 to 10 percent of American college football players sustain a concussion in a given year, so meaningful comparisons demand dozens of schools and hundreds of athletes.
The panel then piled on further obstacles with admirable candor. Gualano pointed out that so many athletes already take creatine that assembling a clean placebo group will be genuinely difficult. Rawson added that concussion itself resists tidy study: injuries differ by type and brain location, recovery times swing from days to months with dramatic outliers, and in some sports athletes hide symptoms to avoid being pulled from play. His suggestion for the meantime was pragmatic. Rather than wait years for the definitive trial, researchers can run rigorous case studies and carefully track athletes who voluntarily take creatine against those who do not, comparing injury prevalence and recovery time, in the spirit of Greenwood’s earlier surveillance work. Much of that data, he noted, may already be sitting in athletic training rooms across the country.
This is what honest science communication looks like: the same researchers who believe creatine probably helps are the ones itemizing every reason the proof does not exist yet.
Creatine and the Menstrual Cycle
An audience member proposed an elaborate protocol: pair the luteal phase with higher strength training volume and 5 grams of creatine daily, then pair the follicular phase with more endurance work and 3 grams daily. Is that the optimal approach?
Smith-Ryan, who leads much of the research on creatine in women, answered simply: she has seen no evidence that dosing needs to change across the menstrual cycle. The one adjustment she could imagine is timing a short loading phase to the luteal phase, allowing quicker saturation ahead of a block of higher training volume, since hormonal shifts in that phase may influence performance. Otherwise, a daily 5 gram dose is sufficient throughout the cycle. It simply takes longer to reach full saturation than loading does, a pattern established decades ago by Hultman and colleagues, who showed that around 20 grams per day saturates muscle in under a week while about 3 grams per day arrives at a similar place over roughly a month.
Her broader research supports treating creatine as particularly relevant for women rather than as a male supplement borrowed by women. In a 2021 review in Nutrients, Smith-Ryan and colleagues describe how creatine kinetics appear to vary with hormonal state across the menstrual cycle, pregnancy, the postpartum period, and menopause, and conclude that supplementation is effective for strength and performance in women before menopause, with emerging interest in mood and cognition benefits as well.
A follow up question asked about hormonal contraceptives, and here Smith-Ryan was careful to separate expectation from knowledge. The honest answer, she said, is that we do not yet know how contraceptives interact with creatine supplementation. Her educated expectation is that monophasic birth control pills, the most common form in the United States, follow a hormonal pattern similar enough to a natural cycle that the creatine response should look similar to that of women with regular natural cycles. Localized hormone delivery, such as a hormonal IUD, is a larger unknown. She flagged this as an important open research question rather than settled science, and that framing deserves respect: it is speculation, clearly labeled as such by the researcher herself.
Creatine in Medical Rehabilitation
Another questioner asked Harmon to choose the three patient groups who would benefit most from creatine during rehabilitation. She resisted the premise, and her reasoning is worth hearing in full. Based on the body of literature her team reviewed, she suspects nearly every patient population can benefit from creatine in some way. Pressed for specifics, she pointed to muscular dystrophy patients as clear beneficiaries, called the evidence during limb immobilization likely beneficial but in need of further study, and noted recovery from exercise as a well supported use.
Her most interesting point was methodological. When studies in patient populations fail to show improvements, she argued, that does not necessarily mean nothing is happening. Researchers may be measuring the wrong parameters, or using a dose or timeline that does not fit that clinical group. It is a fair caution in both directions: absence of evidence is not evidence of absence, but it is not evidence of presence either.
The independent literature largely supports her tiers. A Cochrane review by Kley and colleagues pooled randomized trials and found that short and medium term creatine supplementation increased muscle strength in people with muscular dystrophies, with good tolerability. The same review is a useful reminder that creatine is not universally helpful in muscle disease: it found no significant benefit in metabolic myopathies, and high doses actually worsened muscle pain in McArdle disease. Harmon’s own 2021 review in Nutrients walks through the rationale and evidence for creatine in muscle disuse and rehabilitation settings, including immobilization and aging, and reaches a similarly measured conclusion: strong mechanistic logic, encouraging results in several populations, and a need for larger trials with better matched doses and outcomes.
For anyone facing surgery, injury, or a period of enforced inactivity, the practical translation is that creatine is a reasonable, low risk conversation to have with your medical team, not a substitute for rehabilitation itself.
Upper Body Versus Lower Body
A more technical audience question asked why creatine might behave differently in the lower limbs than the upper limbs, and whether any study has directly compared the two. The exchange that followed was a small masterclass in reading research critically.
Candow offered a hypothesis for older adults: aging brings substantial loss of type 2 muscle fibers, particularly in the lower limbs, so creatine may show preferential benefits there precisely because it is pushing against the strongest current of decline. That matters clinically, he stressed, because lower limb strength in older adults is about reducing falls and fractures. He also recalled a study, with Brad Schoenfeld among the authors, that looked at regional differences in creatine’s effects and found the upper body responded more, though in a younger population. That study checks out: Nunes and colleagues put resistance trained men through eight weeks of training with creatine or placebo and found creatine produced greater muscle growth in the upper limbs and trunk than in the lower limbs.
Kreider then added the caution every supplement reader should internalize. You cannot judge creatine’s efficacy by comparing one body part to another without asking how familiar the test is. In his studies with football players in the 1990s, everyone had years of bench press experience, so upper body tests showed consistent improvement, while squats and cleans involve far more technical variability, which muddies the results. He has never seen evidence that a shoulder muscle retains more creatine than a leg muscle. Small differences may exist due to fiber type, but in general muscle creatine rises by about 20 to 30 percent with supplementation, depending on where you start. That figure traces to the foundational work of Harris, Soderlund, and Hultman, who showed in 1992 that repeated 5 gram doses raise muscle creatine substantially, with the biggest gains in people with the lowest starting levels. In other words, apparent regional differences may say more about how we measure performance than about where creatine goes.
Creatine and Type 2 Diabetes
An audience member asked Gualano to explain the relationship between creatine and glycated hemoglobin, the long term blood sugar marker better known as HbA1c, in light of exercise and diet. His answer was appropriately modest about mechanism while standing firmly on his data.
In his group’s trial, Gualano explained, exercise training appears to have mediated the effect: creatine amplified what training did for insulin sensitivity, and that combination lowered HbA1c. At the molecular level, he pointed to increased translocation of GLUT4, the transporter that moves to the surface of muscle cells to pull glucose out of the bloodstream, as the most likely explanation among the signaling changes his team observed.
The trial itself, published in Medicine and Science in Sports and Exercise in 2011, randomized patients with type 2 diabetes to creatine or placebo alongside a supervised exercise program lasting twelve weeks, in a double blind design. The creatine group saw a significant reduction in HbA1c compared with the placebo group, and the improvement tracked with GLUT4 moving to the muscle cell membrane. It remains one of the more striking findings in clinical creatine research, and also one that needs replication: it was a single, small trial, and creatine was an addition to exercise, not a replacement for it or for medication. Anyone with diabetes should treat this as a promising area to discuss with their physician, particularly since blood sugar management and kidney health require individual medical oversight.
Creatine and Caffeine
The final question went to Smith-Ryan, and it is one of the most searched questions in all of sports nutrition: should creatine and caffeine be mixed, or do they cancel each other out?
Her answer, drawn from data her group published and from the field’s broader consensus, was reassuring with one caveat. If you want the full benefits of creatine, very high doses of caffeine could impair them. But both supplements are effective, and at moderate intakes she sees no reason to choose. Her advice was to go ahead and enjoy both.
Kreider backed her up with a piece of history. The concern originated with a 1996 study by Vandenberghe and colleagues, which found that caffeine taken during a creatine loading phase eliminated creatine’s benefit on muscle torque production. Yet when Kreider discussed this years ago with Roger Harris, whose 1992 study launched modern creatine supplementation, Harris pointed out that the original creatine studies dissolved the powder in hot tea, meaning caffeine was present in the very experiments that proved creatine works. Kreider’s conclusion is that there is probably not much to the interaction. He added a subtler point: since caffeine and creatine each improve performance on their own, they may be synergistic in combination, or each may simply mask some of the other’s measurable benefit in a study, which is not the same as cancellation. Researchers, he noted, have never told people to avoid caffeine with creatine, because that would contradict the foundational studies themselves.
The published record sits between the two poles. A review by Trexler and Smith-Ryan concluded that the evidence for a genuine interference is limited and mechanistically unclear, with the practical concerns concentrated around chronic, very high caffeine intakes during creatine loading. For the ordinary person having coffee in the morning and creatine whenever convenient, the panel’s verdict was unanimous: this combination is fine.
Practical Takeaways
Strip away the conference setting and the panel’s answers reduce to a few clear positions. The core habit is 3 to 5 grams of creatine monohydrate every day, taken consistently. Loading is optional and only changes how fast you saturate, not where you end up, and the same steady dose serves men and women alike, across every phase of the menstrual cycle, based on current evidence.
On safety, the researchers were unambiguous: the 2017 position stand Kreider led describes creatine as safe and well tolerated in healthy people at doses far above what anyone needs, across years of use. That safety record is precisely why the brain conversation has advanced so quickly from laboratory rationale to practical recommendation. For athletes in collision sports, military personnel, and others at high risk of head injury, panelists like Rawson consider a small daily dose prudent right now, because the downside is negligible while the potential upside, entering an injury with fuller brain energy reserves, is meaningful.
At the same time, be clear eyed about what has and has not been shown. Creatine’s muscle and strength benefits rest on hundreds of trials. Its brain benefits rest on modest memory findings, small treatment trials in injured children, animal models, and strong mechanistic logic, with the first true prevention trial only now getting organized in Canada. That is early evidence, honestly labeled, and the researchers building the field said so themselves. If those trials read out positive over the next few years, one of the cheapest supplements in existence may turn out to protect one of the most valuable things you own. Until then, creatine remains what the panel described: a thoroughly proven tool for muscle and performance, a promising adjunct in rehabilitation and metabolic health under medical guidance, and one of the most interesting open questions in brain nutrition.